---
title: "Lilly, AdvanCell to collaborate on alpha treatments for cancer"
date: "2025-02-10 16:28:55"
summary: "Eli Lilly (NYSE:LLY) and AdvanCell have agreed to work together on developing alpha therapies for the treatment of cancer. AdvanCell, which is based in Australia, uses a technology known as an alpha isotope generator \"which addresses the greatest unmet need in targeted alpha therapy – the reliable and scalable supply..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291258680/image_1291258680.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Eli Lilly (NYSE:[LLY](https://seekingalpha.com/symbol/LLY "Eli Lilly and Company")) and AdvanCell have agreed to work together on developing alpha therapies for the treatment of cancer.
* AdvanCell, which is based in Australia, uses a technology known as an alpha isotope generator "which addresses the greatest unmet need in targeted alpha therapy – the reliable and scalable supply of isotope," according to the company's website.
* The [agreement](https://www.businesswire.com/news/home/20250210990350/en/AdvanCell-Enters-Into-Strategic-Collaboration-with-Lilly-to-Advance-Novel-Targeted-Alpha-Therapies-for-the-Treatment-of-Cancer "agreement") calls for the use AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure with Lilly’s drug pipeline to advance a portfolio of targeted alpha therapies.
* AdvanCell's most advanced candidate is ADVC001 in phase 1/2 for prostate cancer.
* Financial terms of the deal were not disclosed.

[seekalpha](https://seekingalpha.com/news/4405544-eli-lilly-advancell-collaborate-alpha-treatments-cancer)
